Insmed

Insmed P/TBV

The Price to Tangible Book Value (P/TBV) of Insmed (INSM) as of Nov 5, 2026 is 52.62. In the previous year, Price to Tangible Book Value (P/TBV) was 350.09 — a change of -84.97% (lower).

P/TBV

52.62

YoY

-84.97%

Last updated:

Price to Tangible Book Value (P/TBV) of Insmed is 2025 52.62 . Price to Tangible Book Value (P/TBV) of Insmed was 2024 350.09 . It decreases by -84.97% lower compared to the previous year.

The Insmed P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
349.04 USD
Jan 1, 2019
205.61 USD
Jan 1, 2020
178.91 USD
Jan 1, 2021
158.18 USD
Jan 1, 2022
-271.24 USD
Jan 1, 2023
-59.66 USD
Jan 1, 2024
350.09 USD
Jan 1, 2025
52.62 USD
The Insmed P/TBV history
YEARP/TBVYoY
52.62-84.97%
350.09-686.80%
-59.66-78.00%
-271.24-271.48%
158.18-11.59%
178.91-12.99%
205.61-41.09%
349.04+169.18%
129.67-84.43%
833.03+412.82%
162.44-64.24%
454.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

Price to Tangible Book Value (P/TBV) of Insmed is 52.62 in 2025.

Price to Tangible Book Value (P/TBV) of Insmed changed from 350.09 to 52.62, representing a -84.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Insmed since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Insmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Insmed

All Key Metrics — Insmed